INOTREM
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that it has filed a patent to protect a new therapeutic modality against TREM-1, a monoclonal antibody.
The filing of this monoclonal antibody patent is a significant milestone for Inotrem’s strategic development as it represents the company’s second asset, next to nangibotide, and a further diversification of its drug portfolio. Moreover, by modulating the activity of the TREM-1 pathway over extended periods of time, this therapeutic modality offers a new and promising alternative for the treatment of chronic inflammatory diseases.
TREM-1 is an immunoreceptor initially discovered for its role in the pathophysiology of acute inflammatory syndromes and in particular septic shock. Since its inception in 2013, Inotrem has introduced the therapeutic peptide nangibotide into the clinics for acute inflammatory syndromes secondary to severe infections. Two Phase IIB clinical trials are currently ongoing in septic shock and COVID-19 patients. Since its discovery in 2000, an increasing number of research work indicated the implication of the therapeutic target TREM-1 in not only acute inflammatory diseases but also in the development of chronic inflammation. Pioneering these approaches, Inotrem initiated in 2019 a proprietary research and discovery program to identify a new modality against TREM-1 in the form of a therapeutic monoclonal antibody, with pharmacological properties suitable for the management of chronic indications.
“Inotrem’s research team’s exceptional commitment is at the core of today’s success. Adding a monoclonal antibody to our therapeutic modalities targeting the TREM-1 pathway now allows us to expand our development efforts beyond the current acute indications to also address chronic inflammatory syndromes with a high unmet medical need,” said Marc Derive, co-founder and Chief Scientific Officer of Inotrem.
“Today’s announcement constitutes a key advancement for Inotrem. This new patent application demonstrates the company’s ability to deploy its vision and strategy. Through its proprietary technology platform addressing inflammatory diseases, it has the potential to develop treatments in a wide number of inflammatory indications, both acute and now chronic, for which there are today no or limited specific treatment. We are looking forward to the clinical development progress of this new asset, with preclinical development slated to start later this year,” said Jean-Jacques Garaud, Executive Vice-President, Head of Scientific and Medical Affairs and Inotrem’s co-founder.
Chronic inflammatory diseases are inflammatory-driven diseases of the digestive system, joints, skin, respiratory system, kidneys, and various other organs. Most of them have no cure, and new biologics have recently reached the market to target inflammation. But there are still a high number of non-responders to these innovative drugs, and therefore a very significant unmet medical need.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapy for inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and COVID-19. In parallel, Inotrem has launched a program to develop new therapeutic modalities targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors. For more information please visit: www.inotrem.com
About TREM-1 pathway
TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting forbedrer sine organisatoriske udviklingskapaciteter med Omni HR Consulting1.8.2025 19:22:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for menneskelige ressourcer gennem en samarbejdsaftale med Omni HR Consulting, et sydafrikansk konsulentfirma med speciale i løsninger til forretnings- og personaleudvikling. Omni HR Consulting tilbyder en komplet pakke af tjenester, der omfatter organisationsudvikling, præstationsrådgivning, akkrediteret uddannelse, kompetenceudvikling og ledelsesprogrammer gennem sit Business and Leadership Academy. Virksomheden samarbejder med kunderne om at designe og implementere løsninger, der retter sig mod medarbejdernes kompetencer, optimering af resultater og strategisk tilpasning og understøttes af en konsekvent tilgang til projektledelse og overholdelse af sydafrikanske kvalitetsstandarder. "Hos Omni tror vi på, at effektiv udvikling starter med forståelse af konteksten," siger administrerende direktør Lize Moldenhauer. "Vi arbejder tæt sammen med vores kunder for at udvikle skræddersyede løsninger, der skaber målbare fremskridt – hvad ente
DevvStream Deploys Crypto Treasury with Initial Bitcoin and Solana Purchases; Intends to Expand Credit Facility to $300M1.8.2025 16:00:00 CEST | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced the initial deployment of its crypto treasury strategy with purchases of Bitcoin ($BTC) and Solana ($SOL), funded by a portion of the first (US)$10 million tranche of its (US)$300 million senior secured convertible notes facility with Helena Global Investment Opportunities 1 Ltd. These acquisitions represent the operational launch of DevvStream’s digital treasury strategy, designed to combine institutional-grade liquidity with blockchain infrastructure. The Company believes Bitcoin provides a liquid, non-correlated store of value and that Solana’s high-throughput network supports the Company’s long-term objectives in, and the industry’s move towards, sustainability-linked tokenization. In parallel, DevvStream announced its intention to increase its existing Equity Line of Credit (ELOC) to (US)$30
BEYOND Launches PASSO, a Sculptural Icon on Palm Jumeirah1.8.2025 15:17:00 CEST | Press release
BEYOND Developments, the forward-thinking real estate brand shaping lifestyle destinations by the sea, has unveiled PASSO, a sculptural waterfront development located on the prestigious West Crescent of Palm Jumeirah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250801880717/en/ PASSO by BEYOND, a Sculptural Icon on Palm Jumeirah. (Photo: AETOSWire) As BEYOND’s first flagship beyond its masterplan in Dubai Maritime City, PASSO marks a defining milestone in the company’s strategic growth to one of the world’s most iconic and desirable destinations. The project launched with a spectacular Palm Jumeirah event featuring Dubai’s first-ever “screens in the sky” show, a 13-minute performance with over 4,000 drones blending immersive visuals and live stage action. Comprising two sculptural towers, Avita and Bella, PASSO offers 625 residences in a refined mix of layouts. From one-bedroom retreats and two-to-four-bedroom-plus lifest
LevelBlue Completes Acquisition of Aon’s Cybersecurity and IP Litigation Consulting Groups1.8.2025 14:00:00 CEST | Press release
Strategic deal enhances LevelBlue's cybersecurity offerings, solidifying its position as the world’s largest leading independent, pure-play MSSP LevelBlue, a global leader in cloud-based, AI-driven managed security services, today announced the completion of its acquisition of Aon’s (NYSE: AON) Cybersecurity and Intellectual Property (IP) Litigation consulting groups, including the renowned cybersecurity firm, Stroz Friedberg, and Elysium Digital. With this completion the consulting group will operate as Stroz Friedberg, a LevelBlue company. This strategic acquisition adds elite cyber and high-tech IP litigation consulting expertise to the LevelBlue portfolio, which includes a globally recognized platform of approximately 300 technology professionals with deep relationships across Fortune 500 companies, 80 percent of the Am Law 100, and most of the UK’s top 20 law firms. As a result, LevelBlue will significantly fortify its incident response and advisory capabilities, while expanding i
SBC Medical to Announce Q2 2025 Financial Results and Hold Conference Call on August 13, 20251.8.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global franchise and provider of services for aesthetic clinics, today announced that it will report its Q2 2025 financial results on Wednesday, August 13, 2025, before the U.S. market opens. The Company will hold a conference call on Wednesday, August 13, 2025 at 8:30 am Eastern Time (or Wednesday, August 13, 2025 at 9:30 pm Japan Time) to discuss the financial results and take questions live. Please register in advance of the conference using the link provided below. https://edge.media-server.com/mmc/p/ukc9sp9j It will automatically direct you to the registration page of “SBC Q2 2025 Financial Results Presentation.” Please follow the steps to enter your registration details, then click “Submit.” Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom